SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 608 ordinary shares on March 19, 2026 in an open‑market transaction at a weighted average price of $4.7908 per share.
The footnotes state the sale was made to satisfy tax obligations from restricted stock units that vested on March 18, 2026 and was executed under a pre‑established Rule 10b5‑1 trading plan, meaning it was not a discretionary trade. Following the sale, Menu directly holds 173,616 shares.
SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $4.7813 per share.
The shares were sold to cover tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan, meaning the trades were not discretionary. After this transaction, Xu directly holds 537,116 Ordinary Shares.
SOPHiA GENETICS SA Chief People Officer sells small block of shares for taxes
Chief People Officer Manuela Valente sold 380 Ordinary Shares of SOPHiA GENETICS SA on March 19, 2026 in an open-market transaction at a weighted average price of $4.7851 per share, with individual sale prices ranging from $4.68 to $4.87.
The shares were sold to satisfy tax obligations from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary trades. After this transaction, Valente directly holds 152,379 Ordinary Shares.
SOPHiA GENETICS SA President Ross Muken reported a small open‑market sale of 1,183 Ordinary Shares at a weighted average price of $4.7937 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan, meaning the transactions were pre-scheduled rather than discretionary. After these sales, Muken directly holds 271,910 Ordinary Shares.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale. On March 18, 2026, he sold 33 Ordinary Shares at an average price of $4.76 per share and continued to hold 92,386 shares afterward.
The company states this was a “sell to cover” transaction executed in the open market solely to satisfy tax obligations tied to vesting restricted stock units, and it did not represent a discretionary trade.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported an open-market sale of 774 Ordinary Shares on March 19, 2026 at a weighted average price of $4.7862 per share. The footnotes state this sale was made solely to satisfy tax withholding obligations from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and was not a discretionary trade. After the transaction, Cardoza directly holds 184,858 Ordinary Shares, indicating this was a small, routine tax-related sale relative to his remaining position.
ZHENYU XU reported 10b5-1 sales of Common Stock under multiple transactions. The filing lists periodic 10b5-1 dispositions on 01/05/2026, 01/06/2026, 01/13/2026, 01/20/2026, 02/13/2026, 02/19/2026, and 03/13/2026, with reported share amounts of 2006, 3000, 4000, 608, 4000, 608, and 4000 respectively and per-trade proceeds shown in the filing.
The filing also lists 608 Restricted Stock Units to be sold by the issuer on 03/18/2026. Transactions were processed through Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC submitted a Form 144 listing 684 Restricted Stock Units to be sold on 03/18/2026 for SOPH. The filing also records prior 10b5-1 dispositions by Daan Guido Maria van Well on 01/05/2026 (2,051 shares), 01/06/2026 (2,056 shares), 01/20/2026 (684 shares) and 02/19/2026 (684 shares).
SOPH: notice of proposed resale of Common Stock tied to Restricted Stock Units. The filing lists 1,183 Restricted Stock Units scheduled on 03/18/2026 for sale. The excerpt also discloses recent Rule 10b5-1 dispositions: examples include 760 shares sold on 02/19/2026 for $3,665.94 and 4,200 shares sold on 01/06/2026 for $20,013.84.
SOPH: A Form 144 notice lists a proposed sale of 774 Restricted Stock Units of Common Stock dated 03/18/2026 by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also records prior 10b5-1 sales of 856 shares on 12/22/2025 attributed to George Cardoza.